Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
In spite of there being a number of vaccines, influenza remains a significant global cause of morbidity and mortality. Understanding more about natural and vaccine induced immune protection against influenza infection would help to develop better vaccines. Virus specific IgG is a known correlate of protection, but other factors may help to reduce viral load or disease severity, for example IgA. In the current study we measured influenza specific responses in a controlled human infection model using influenza A/California/2009 (H1N1) as the challenge agent. Volunteers were pre-selected with low haemagglutination inhibition (HAI) titres in order to ensure a higher proportion of infection; this allowed us to explore the role of other immune correlates. In spite of HAI being uniformly low, there were variable levels of H1N1 specific IgG and IgA prior to infection. There was also a range of disease severity in volunteers allowing us to compare whether differences in systemic and local H1N1 specific IgG and IgA prior to infection affected disease outcome. H1N1 specific IgG level before challenge did not correlate with protection, probably due to the pre-screening for individuals with low HAI. However, the length of time infectious virus was recovered from the nose was reduced in patients with higher pre-existing H1N1 influenza specific nasal IgA or serum IgA. Therefore, IgA contributes to protection against influenza and should be targeted in vaccines.
Date Issued
2017-05-17
Date Acceptance
2017-05-03
Citation
Frontiers in Microbiology, 2017, 8
ISSN
1664-302X
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Microbiology
Volume
8
Copyright Statement
© 2017 Gould, Francis, Anderson, Georges, Cope and Tregoning. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Sponsor
Commission of the European Communities
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401580600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
280873
RDA02 79560
Subjects
Science & Technology
Life Sciences & Biomedicine
Microbiology
influenza
IgA
nasal
vaccine
Human Infection Challenge study
RESPIRATORY SYNCYTIAL VIRUS
A VIRUS
ANTIVIRAL RESISTANCE
INFECTION
VACCINE
LIVE
RESPONSES
ADULTS
TRANSMISSION
ADJUVANT
Publication Status
Published
Article Number
ARTN 900